<p>Tyra Biosciences, Inc. (NASDAQ:TYRA - 获取免费报告) 的股价在周三达到了新的 52 周高点。该公司交易最高达到 28.25 美元，最后交易价格为 28.5290 美元，成交量为 68587 股。该股票此前收盘价为 26.40 美元。</p>
<p>获取 <strong>Tyra Biosciences</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<p>TYRA 最近成为几份分析师报告的主题。华尔街禅在周日的研究报告中将 Tyra Biosciences 的股票评级从 “卖出” 上调至 “持有”。Wedbush 在 12 月 16 日的报告中将 Tyra Biosciences 的目标价格从 30.00 美元提高至 37.00 美元，并给予该股票 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日的报告中重申了对 Tyra Biosciences 股票的 “卖出（d-）” 评级。最后，Oppenheimer 在 9 月 10 日的研究报告中重申了 “跑赢大盘” 的评级，并设定了 36.00 美元的目标价格。一个投资分析师给予该股票 “强烈买入” 评级，四个分析师给予 “买入” 评级，一个分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，Tyra Biosciences 目前的平均评级为 “适度买入”，平均目标价格为 34.20 美元。</p>
<p><strong>查看我们最新的 TYRA 股票报告</strong></p>
<h2>Tyra Biosciences 股价上涨 9.9%</h2>
<p>该股票的 50 日移动平均价格为 20.93 美元，200 日移动平均价格为 15.06 美元。该股票的市值为 15.5 亿美元，市盈率为-15.42，贝塔值为 1.07。</p>
<p>Tyra Biosciences (NASDAQ:TYRA - 获取免费报告) 最近在 11 月 5 日发布了其财报。该公司报告季度每股收益为（0.50 美元），符合分析师的共识预期（0.50 美元）。分析师预计 Tyra Biosciences, Inc.在本年度的每股收益将为-1.57。</p>
<h2>内部买卖</h2>
<p>在其他 Tyra Biosciences 的新闻中，董事 Robert J. More 在 12 月 19 日的交易中出售了 10,000 股该公司的股票。股票以平均价格 25.00 美元出售，总交易额为 250,000.00 美元。交易后，该董事直接持有 3,823,425 股公司的股票，估值约为 95,585,625 美元。此次交易使其持股减少了 0.26%。该出售在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站访问。15.20% 的股票由内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>大型投资者最近买入和卖出了该公司的股票。Federated Hermes Inc.在第三季度将其在 Tyra Biosciences 的持股增加了 586.3%。Federated Hermes Inc.现在拥有 2,155 股该公司的股票，价值 30,000 美元，此前在上个季度购买了 1,841 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第二季度将其在 Tyra Biosciences 的持股增加了 14.5%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 13,182 股该公司的股票，价值 126,000 美元，此前在上个季度购买了 1,668 股。SG Americas Securities LLC 在第三季度购买了价值 133,000 美元的 Tyra Biosciences 新头寸。俄亥俄州公共雇员退休系统在第二季度购买了价值约 177,000 美元的 Tyra Biosciences 新头寸。最后，Russell Investments Group Ltd.在第三季度将其在 Tyra Biosciences 的持股增加了 27.7%。Russell Investments Group Ltd.现在拥有 12,741 股该公司的股票，价值 178,000 美元，此前在上个季度购买了 2,766 股。84.14% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Tyra Biosciences 公司简介</h2>
<p>(获取免费报告)</p>
<p>Tyra Biosciences NASDAQ: TYRA 是一家临床阶段的精准肿瘤学公司，专注于为基因定义的癌症发现和开发小分子疗法。该公司整合生物信息学、分子生物学和药物化学，以识别致癌驱动因子并设计靶向抑制剂。通过利用大规模基因组数据集和功能筛选，Tyra Biosciences 旨在推进满足患者群体高未满足医疗需求的疗法。</p>
<p>该公司的产品管线包括多个处于不同开发阶段的项目，每个项目针对癌细胞中的特定分子脆弱性。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更喜欢的五只股票比 Tyra Biosciences 更好</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>这只股票获得 94 分（满分 100 分）</li>
<li>将这些代码输入你的普通经纪账户</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Tyra Biosciences 吗？</h2>
<p>在考虑 Tyra Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Tyra Biosciences 并不在名单上。</p>
<p>虽然 Tyra Biosciences 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TYRA

<p>Tyra Biosciences（纳斯达克代码：TYRA）达到了新的 52 周高点 28.53 美元，较之前的收盘价 26.40 美元上涨。分析师的评级各不相同，其中一位为强烈买入，四位为买入，一位为卖出。平均目标价为 34.20 美元。该公司报告的每股收益为-0.50 美元，符合预期。内部交易方面，董事 Robert J. More 出售了 10,000 股。机构投资者持有该股票的 84.14%。Tyra 专注于开发针对基因定义癌症的疗法</p>

<p>Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report)'s stock price reached a new 52-week high on Wednesday . The company traded as high as $28.25 and last traded at $28.5290, with a volume of 68587 shares changing hands. The stock had previously closed at $26.40.</p>
<div class="lb-trans"><p>Tyra Biosciences, Inc. (NASDAQ:TYRA - 获取免费报告) 的股价在周三达到了新的 52 周高点。该公司交易最高达到 28.25 美元，最后交易价格为 28.5290 美元，成交量为 68587 股。该股票此前收盘价为 26.40 美元。</p>
</div><p>Get <strong>Tyra Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tyra Biosciences</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>TYRA has been the subject of several recent analyst reports. Wall Street Zen raised shares of Tyra Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday. Wedbush increased their price target on Tyra Biosciences from $30.00 to $37.00 and gave the stock an &#34;outperform&#34; rating in a report on Tuesday, December 16th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Tyra Biosciences in a report on Wednesday, October 8th. Finally, Oppenheimer reaffirmed an &#34;outperform&#34; rating and set a $36.00 target price on shares of Tyra Biosciences in a research report on Wednesday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Tyra Biosciences presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $34.20.</p>
<div class="lb-trans"><p>TYRA 最近成为几份分析师报告的主题。华尔街禅在周日的研究报告中将 Tyra Biosciences 的股票评级从 “卖出” 上调至 “持有”。Wedbush 在 12 月 16 日的报告中将 Tyra Biosciences 的目标价格从 30.00 美元提高至 37.00 美元，并给予该股票 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日的报告中重申了对 Tyra Biosciences 股票的 “卖出（d-）” 评级。最后，Oppenheimer 在 9 月 10 日的研究报告中重申了 “跑赢大盘” 的评级，并设定了 36.00 美元的目标价格。一个投资分析师给予该股票 “强烈买入” 评级，四个分析师给予 “买入” 评级，一个分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，Tyra Biosciences 目前的平均评级为 “适度买入”，平均目标价格为 34.20 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on TYRA</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 TYRA 股票报告</strong></p>
</div><h2>Tyra Biosciences Trading Up 9.9%</h2>
<div class="lb-trans"><h2>Tyra Biosciences 股价上涨 9.9%</h2>
</div><p>The stock's fifty day moving average price is $20.93 and its 200 day moving average price is $15.06. The stock has a market cap of $1.55 billion, a P/E ratio of -15.42 and a beta of 1.07.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均价格为 20.93 美元，200 日移动平均价格为 15.06 美元。该股票的市值为 15.5 亿美元，市盈率为-15.42，贝塔值为 1.07。</p>
</div><p>Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, hitting analysts' consensus estimates of ($0.50). On average, analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.</p>
<div class="lb-trans"><p>Tyra Biosciences (NASDAQ:TYRA - 获取免费报告) 最近在 11 月 5 日发布了其财报。该公司报告季度每股收益为（0.50 美元），符合分析师的共识预期（0.50 美元）。分析师预计 Tyra Biosciences, Inc.在本年度的每股收益将为-1.57。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other Tyra Biosciences news, Director Robert J. More sold 10,000 shares of the business's stock in a transaction on Friday, December 19th. The shares were sold at an average price of $25.00, for a total transaction of $250,000.00. Following the transaction, the director directly owned 3,823,425 shares of the company's stock, valued at approximately $95,585,625. The trade was a 0.26% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. 15.20% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Tyra Biosciences 的新闻中，董事 Robert J. More 在 12 月 19 日的交易中出售了 10,000 股该公司的股票。股票以平均价格 25.00 美元出售，总交易额为 250,000.00 美元。交易后，该董事直接持有 3,823,425 股公司的股票，估值约为 95,585,625 美元。此次交易使其持股减少了 0.26%。该出售在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站访问。15.20% 的股票由内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Large investors have recently bought and sold shares of the business. Federated Hermes Inc. lifted its holdings in shares of Tyra Biosciences by 586.3% during the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company's stock valued at $30,000 after purchasing an additional 1,841 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Tyra Biosciences by 14.5% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company's stock worth $126,000 after acquiring an additional 1,668 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Tyra Biosciences during the third quarter valued at $133,000. Public Employees Retirement System of Ohio purchased a new position in shares of Tyra Biosciences in the 2nd quarter worth about $177,000. Finally, Russell Investments Group Ltd. boosted its stake in Tyra Biosciences by 27.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company's stock worth $178,000 after purchasing an additional 2,766 shares in the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该公司的股票。Federated Hermes Inc.在第三季度将其在 Tyra Biosciences 的持股增加了 586.3%。Federated Hermes Inc.现在拥有 2,155 股该公司的股票，价值 30,000 美元，此前在上个季度购买了 1,841 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第二季度将其在 Tyra Biosciences 的持股增加了 14.5%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 13,182 股该公司的股票，价值 126,000 美元，此前在上个季度购买了 1,668 股。SG Americas Securities LLC 在第三季度购买了价值 133,000 美元的 Tyra Biosciences 新头寸。俄亥俄州公共雇员退休系统在第二季度购买了价值约 177,000 美元的 Tyra Biosciences 新头寸。最后，Russell Investments Group Ltd.在第三季度将其在 Tyra Biosciences 的持股增加了 27.7%。Russell Investments Group Ltd.现在拥有 12,741 股该公司的股票，价值 178,000 美元，此前在上个季度购买了 2,766 股。84.14% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Tyra Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Tyra Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Tyra Biosciences NASDAQ: TYRA is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.</p>
<div class="lb-trans"><p>Tyra Biosciences NASDAQ: TYRA 是一家临床阶段的精准肿瘤学公司，专注于为基因定义的癌症发现和开发小分子疗法。该公司整合生物信息学、分子生物学和药物化学，以识别致癌驱动因子并设计靶向抑制剂。通过利用大规模基因组数据集和功能筛选，Tyra Biosciences 旨在推进满足患者群体高未满足医疗需求的疗法。</p>
</div><p>The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于不同开发阶段的项目，每个项目针对癌细胞中的特定分子脆弱性。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Tyra Biosciences</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>Do not delete, read immediately</li>
<li>You Still Think Silver’s a Joke? Watch What Happens Next.</li>
<li>This stock gets a 94 out of 100</li>
<li>Punch these codes into your ordinary brokerage account</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Tyra Biosciences 更好</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>这只股票获得 94 分（满分 100 分）</li>
<li>将这些代码输入你的普通经纪账户</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tyra Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Tyra Biosciences 吗？</h2>
</div><p>Before you consider Tyra Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Tyra Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Tyra Biosciences 并不在名单上。</p>
</div><p>While Tyra Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tyra Biosciences 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tyra Biosciences（NASDAQ:TYRA）创下 12 个月新高 - 以下是原因